ClinicalTrials.gg

TargetBeta

ESR1

estrogen receptor 1 · also ER, NR3A1, Era, ER-alpha · Estrogen receptors

15 programs in company-led studies act on ESR1, from 12 companies: 9 in phase 3, 5 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (12 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
FulvestrantruleAstraZenecaphase 4305 running–ChEMBL
TamoxifenruleAstraZenecaphase 4214 running–ChEMBL
Ethinyl EstradiolruleJohnson & Johnsonphase 4701 running–ChEMBL
EstradiolruleNovo Nordiskphase 4691 running–ChEMBL
ClomipheneruleHamad Medicalphase 431 running–ChEMBL
giredestrantHoffmann-La Rochephase 31712 running–a judged reading
HRS-8080Jiangsu HengRui Medicinephase 31310 running–the company's pipeline
camizestrantruleAstraZenecaphase 3189 running–NCIt
vepdegestrantrulePfizerphase 3206 running–NCIt
ImlunestrantruleEli Lillyphase 3126 running–NCIt
elacestrantruleMenarini Groupphase 3125 running–NCIt
SIM0270ruleSimcere Pharmaceutical Groupphase 354 running–the studies' text
palazestrantruleOlema Pharmaceuticalsphase 343 running–NCIt
taragarestrantruleInventisBiophase 351 running–NCIt
Estrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0117Johnson & Johnsonphase 111 running–a judged reading

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.